$SRNE BRAZILIAN HEALTH REGULATORY AGENCY (ANVISA) AUTHORIZES SORRENTO THERAPEUTICS’ LARGE PHASE 2 CLINICAL TRIAL OF ABIVERTINIB IN MILD, MODERATE AND SEVERE COVID-19 PATIENTS Sorrento aims to recruit 400 participants in the Brazil trial
  • 1
1 Like